Bank of New York Mellon
IMMX icon

Bank of New York Mellon’s Immix Biopharma IMMX Stock Holding History

Bank of New York Mellon’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Buy
235,720
+152,109
+182% +$1.41M ﹤0.01% 2830
2026
Q1 		$762K Sell
83,611
-15,121
-15% -$111K ﹤0.01% 3377
2025
Q4 		$516K Buy
+98,732
New +$406K ﹤0.01% 3598

Other funds holding IMMX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
LFM
LGT Fund Management Vaduz, Liechtenstein $2.4B AUM 38.22% 1-Year Est. Return
IFWM
Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's IMMX Position: Q2 2026 in Review

Bank of New York Mellon increased its Immix Biopharma (IMMX) stake by 182% in Q2 2026, buying an estimated $1.41M and bringing the position to 235,720 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2830.

Bank of New York Mellon first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. 34 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Bank of New York Mellon held 235,720 shares of Immix Biopharma worth $2.43M as of Q2 2026.
  • Bank of New York Mellon bought 152,109 Immix Biopharma shares in Q2 2026, an estimated $1.41M.
  • Immix Biopharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2830 holding.
  • Bank of New York Mellon first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 34 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.